Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase Inhibitor in Liver Transplantation

Completed

• Conditions: Liver Transplantation
• Interventions: Combination Product: PVHA or TACE

• Registration Number: NCT05448339
• Lead Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Brief Summary

To investigate the value of tumor feeding vessels deprivation combined with tyrosine kinase inhibitor in liver transplantation. Patients are enrolled into two groups according to the downstaging therapy they undergo before transplantion.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-01-01
• Study First Submitted: 2022-06-29
• Study First Submitted QC: 2022-07-03
• Study First Posted: 2022-07-07
• Primary Completion: 2023-12-31
• Status Verified: 2024-01
• Study Completion: 2024-01-01
• Last Update Submitted: 2024-01-07
• Last Update Posted: 2024-01-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 197

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
PVHA	PVHA or TACE	Patients undergo tumor feeding vessels deprivation
TACE	PVHA or TACE	Patients undergo TACE therapy

Primary Outcome Measures

Name	Time	Method
Underwent LT	January 2013 and December 2020	Underwent LT
Successful downstaging	January 2013 and December 2020	Successful downstaging

Secondary Outcome Measures

Name	Time	Method
Survival time of patients	January 2013 and December 2020	Survival time of patients
AFP reduction of patients	January 2013 and December 2020	AFP reduction of patients
Recurrence of patients	January 2013 and December 2020	Recurrence of patients

Trial Locations

Locations (1)

Shanghai General Hospital; 🇨🇳 Shanghai, Shanghai, China